Loading...
•
Mar 31
Zomedica Q1 2025 Earnings Report
Zomedica reported a Q1 net loss of $63.8 million due to a $55.8 million non-cash impairment charge, despite achieving record revenue of $6.5 million.
Key Takeaways
Zomedica delivered record Q1 revenue led by growth in therapeutic devices and consumables, but posted a significant net loss driven by a large impairment charge.
Revenue reached $6.5 million, a 4% increase year-over-year.
Gross margin improved to 68%, up from 66% in Q1 2024.
Net loss expanded to $63.8 million due to a $55.8 million impairment.
Adjusted EBITDA loss was $5.7 million, slightly higher than Q1 2024.
Zomedica
Zomedica
Zomedica Revenue by Segment
Revenue by Segment
Therapeutic Devices Revenue
CapyFin.comDiagnostics Revenue
CapyFin.comTRUFORMA Revenue
CapyFin.com Forward Guidance
Zomedica expressed confidence in accelerating adoption of its product portfolio, supported by strong balance sheet and international growth.
Positive Outlook
- Continued growth of PulseVet and TRUFORMA product lines.
- Introduction of new VETIGEL product line.
- Expansion in international markets with 32% YoY growth.
- Strong gross margin performance at 68%.
- Solid liquidity position with $65M in cash and equivalents.
Challenges Ahead
- Significant net loss driven by impairment charge.
- Diagnostics segment revenue declined 25% YoY.
- Capital equipment revenue declined due to lack of large distribution orders.
- Adjusted EBITDA loss increased slightly from Q1 2024.
- Continued operating losses despite revenue growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income